Biomarkers for chemotherapy and drug resistance in the mismatch repair pathway.
Clin Chim Acta
; 544: 117338, 2023 Apr 01.
Article
en En
| MEDLINE
| ID: mdl-37060988
Drugs targeting DNA repair have developed rapidly in cancer therapy, and numerous inhibitors have already been utilized in preclinical and clinical stages. To optimize the selection of patients for treatment, it is essential to discover biomarkers to anticipate chemotherapy response. The DNA mismatch repair (MMR) pathway is closely correlated with cancer susceptibility and plays an important role in the occurrence and development of cancers. Here, we give a concise introduction of the MMR genes and focus on the potential biomarkers of chemotherapeutic response and resistance. It has been clarified that the status of MMR may affect the outcome of chemotherapy. However, the specific underlying mechanisms as well as contradictory results continue to raise considerable controversy and concern. In this review, we summarize the current literature to provide a general overview.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Reparación de la Incompatibilidad de ADN
/
Neoplasias
Límite:
Humans
Idioma:
En
Año:
2023
Tipo del documento:
Article